Compare WIX & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIX | AAPG |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2024 |
| Metric | WIX | AAPG |
|---|---|---|
| Price | $80.11 | $18.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $134.67 | $48.40 |
| AVG Volume (30 Days) | ★ 1.5M | 4.2K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.80 | $290.34 |
| Revenue Next Year | $13.21 | N/A |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $16.36 |
| 52 Week High | $190.92 | $48.45 |
| Indicator | WIX | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 55.27 |
| Support Level | $75.00 | $18.56 |
| Resistance Level | $81.44 | $20.40 |
| Average True Range (ATR) | 5.11 | 0.42 |
| MACD | 1.75 | 0.15 |
| Stochastic Oscillator | 99.76 | 92.75 |
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years, it has invested heavily and introduced its Wix Studio offering for partners, which are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.